Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus and Tacrolimus for GVHD Prophylaxis After Matched Related Allogeneic HSCT
NCT00144703Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2002
- Primary completion
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sirolimus in graft-versus-host disease (GVHD), sponsored by Dana-Farber Cancer Institute. Started Jul 2002; status: completed.
02
Drugs
sirolimus
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00144703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00144703.